Program
romaciclib
Its studies are mostly in Leukemia, Myeloid, Acute · Primary Myelofibrosis, led by Ryvu Therapeutics.
Furthest: phase 2, since Sep 7, 20215 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ryvu Therapeutics | 52 open or running | phase 2since Sep 7, 2021 | Sep 7, 2021 | Dec 2026phase 2 · NCT06987058 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2021First study: phase 2 study in RecurrenceFirst studyNCT05052255 · 66 enrolled · Poland, Spain
- Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteNCT06191263 · 98 planned · France, Italy, Poland and more
- Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06268574 · 62 enrolled · France, Italy, Poland and more
- Apr 29, 2024Phase 2 study in Primary MyelofibrosisNCT06397313 · 36 enrolled · Italy, Poland
- May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT06987058 · 14 planned · France, Poland
Ahead
- Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06987058
- Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06191263
TargetBeta
CDK8 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), ”NCIt, by rule
Other programs on CDK8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SEL-120rule | Ryvu Therapeutics | phase 2 | 7 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06987058Leukemia, Myeloid, Acute · France, Poland | 2 | By invitation | Dec 2026 | 14 |
| NCT06397313Primary Myelofibrosis · Italy, Poland | 2 | Terminated | Jun 30, 2026 | 36 |
| NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Terminated | Jun 30, 2025 | 62 |
| NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Recruiting | Aug 2027 | 98 |
| NCT05052255Recurrence · Poland, Spain | 2 | Terminated | Oct 2, 2025 | 66 |
How it is read
Names in the registry
- “RVU120”, 5 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Primary Myelofibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.